Limax is still poorly understood. Preliminary morphological and molecular data suggest that many unnamed or unrecognised species exist, especially in the Alps, the Mediterranean and the Balkans.Despite their large size, striking colouration and genital extravagance, the taxonomy of the European giant keelback slugs of the genus L.cinereoniger Wolf 1803 and describe it as L.pseudocinereoniger.We organised a citizen science expedition to Durmitor National Park in Montenegro and discovered a new species, genetically distinct, but morphologically similar to the sympatric  Limax. In general, these terrestrial animals  are well-known for their size and colour pattern . What also speaks to the imagination are their genitals  to involve the general public in species discovery in biodiversity hotspots and to engage them in the description and publication of species new to science. Although early initiatives to involve citizen scientists in systematics studies did not move beyond the mere collecting of data  morphologically distinct from L.cinereoniger.During the 2018 trip, we found and sequenced three large  earlier . Upon coLimax specimens were collected by expedition members on two separate taxon expeditions to Durmitor National Park, Montenegro, 10-19 July 2018 and 9-18 July 2019. In addition, specimens were collected by the first author, M. Schilthuizen, in the summers of 2018 and 2019 in other locations in Montenegro. Specimens were retrieved from under logs and rocks on the forest floor, under overhanging rocks, in crevices in limestone and behind loose bark of dead trees. Individuals of mature size were photographed alive , relaxed overnight in water without air bubbles and then transferred into 70% ethanol. The ethanol was refreshed once or twice in the following days or weeks. Tissue samples of up to 10 mm3 were taken from the side of the sole or the keel and preserved in 96% ethanol for further molecular work. The details for specimens that were referred to L.pseudocinereoniger have been listed under "Types" in the description of that species below. The details for two specimens of L.cinereoniger  are as follows: Montenegro, Durmitor National Park, Tara Canyon, 43.18136°N, 19.24084°E, 794 m elev., 13 July 2018, locality code: TxEx-DU0040, leg. I. Njunjić & Taxon Expedition participants, 2 adults (dissected and DNA-barcoded). All material is stored in the Taxon Expeditions Collection, Leiden (collection coden TXEX), Leiden, the collection of Naturalis Biodiversity Center, Leiden (collection coden RMNH) and the Zoologische Staatssammlung München (collection coden SNSB-ZSM).L.cinereoniger, we only used our own specimens of both species from Montenegro (see above under Fieldwork) and only those for which the species identity had been confirmed with a DNA barcode, i.e. the individuals marked with TxEx-DU locality codes in Fig. L.cinereoniger, deviates to some extent from the one of For the descriptions of the morphology and the morphological differentiation of the new species from www.boldsystems.org). They are accessible under numbers TXEX039-19 – TXEX045-19 and TXEX048-19. To determine the species identities, we obtained all sequences of the cytochrome c oxidase subunit I (COI) barcoding region labelled in Limaxcinereoniger’, ‘Limaxcf.cinereoniger’ and ‘Limax “pseudocinereoniger”’ from GenBank. All sequences (newly generated as well as mined from GenBank) were aligned in Geneious Prime v.2020.0.4 using the MUSCLE algorithm (Lehmanniamarginata (Genbank FJ606455) was used as outgroup to root the trees.Tissue samples (prepared as described above) from eight individuals  were analysed genetically with a portable field lab, as described previously . DNA waslgorithm  and defalgorithm , with a Schilthuizen, Thompson, de Vries, van Peursen, Reisinger, Paterno, Maestri, Marcolungo, Esposti, Delledonne & Njunjić, 2022sp. n.F2336F99-5594-589F-B818-BE0F84DE63CF3944596F-E524-4EED-97DB-FBA2A028687BStylommatophora A. Schmidt, 1855Suborder Limacoidea Lamarck, 1801Superfamily Limacidae Lamarck, 1801Family Limax Linnaeus, 1758Genus Limaxmaximus Linnaeus, 1758 Type species:  synonyms:Limaxpseudocinereoniger” Nitz (2013) “Type status:Holotype. Occurrence: occurrenceDetails: http://www.boldsystems.org/index.php/API_Public/specimen?ids=TxExDU0122|TxExPR0004|TxExDU0041|TxExDU0112|TxExDU0121; recordNumber: TxExDU0041; recordedBy: Taxon Expeditions participants; individualID: TxExDU0041; individualCount: 1; sex: H; associatedMedia: http://www.boldsystems.org/pics/TXEX/slug_3+1577602544.jpg|http://www.boldsystems.org/pics/TXEX/Giant_slug+1577607140.JPG|http://www.boldsystems.org/pics/TXEX/slug_3_lateral+1577604939.jpg|http://www.boldsystems.org/pics/TXEX/slug_3_ventral+1577605013.jpg|http://www.boldsystems.org/pics/TXEX/slug_3_dorsal+1577604893.jpg; Taxon: scientificName: Limaxpseudocinereoniger; phylum: Mollusca; class: Gastropoda; order: Stylommatophora; family: Limacidae; genus: Limax; specificEpithet: pseudocinereoniger; Location: country: Montenegro; decimalLatitude: 43.2189; decimalLongitude: 19.1759; Event: eventDate: 18-07-2018; habitat: under rocky overhang; Record Level: institutionCode: Taxon Expeditions B.V.; basisOfRecord: PreservedSpecimenType status:Paratype. Occurrence: occurrenceDetails: http://www.boldsystems.org/index.php/API_Public/specimen?ids=TxExDU0122|TxExPR0004|TxExDU0041|TxExDU0112|TxExDU0121; recordNumber: TxExDU0122; recordedBy: Menno Schilthuizen; individualID: TxExDU0122; individualCount: 1; sex: H; associatedMedia: http://www.boldsystems.org/pics/TXEX/slug_4+1577602643.jpg|http://www.boldsystems.org/pics/TXEX/DU0122lateral+1577615238.jpg|http://www.boldsystems.org/pics/TXEX/DU0122ventral+1577615289.jpg|http://www.boldsystems.org/pics/TXEX/slug_4_dorsal+1577605110.jpg|http://www.boldsystems.org/pics/TXEX/DU0122dorsal+1577615162.jpg|http://www.boldsystems.org/pics/TXEX/slug_4_lateral+1577605161.jpg|http://www.boldsystems.org/pics/TXEX/slug_4_ventral+1577605254.jpg; Taxon: scientificName: Limaxpseudocinereoniger; phylum: Mollusca; class: Gastropoda; order: Stylommatophora; family: Limacidae; genus: Limax; specificEpithet: pseudocinereoniger; Location: country: Montenegro; decimalLatitude: 43.169; decimalLongitude: 18.999; Identification: identifiedBy: Menno Schilthuizen; Record Level: institutionCode: Taxon Expeditions B.V.; basisOfRecord: PreservedSpecimenType status:Paratype. Occurrence: occurrenceDetails: http://www.boldsystems.org/index.php/API_Public/specimen?ids=TxExDU0122|TxExPR0004|TxExDU0041|TxExDU0112|TxExDU0121; recordNumber: TxExDU0112; recordedBy: M. Schilthuizen & I. Njunjić; individualID: TxExDU0112; individualCount: 1; sex: H; associatedMedia: http://www.boldsystems.org/pics/TXEX/TxEx-DU0112-Lim-dorsal+1577602220.jpg|http://www.boldsystems.org/pics/TXEX/slug_5_lateral+1577605397.jpg|http://www.boldsystems.org/pics/TXEX/slug_5_dorsal+1577605353.jpg|http://www.boldsystems.org/pics/TXEX/slug_5+1577602761.jpg|http://www.boldsystems.org/pics/TXEX/TxEx-DU0112-Lim-ventral+1577602257.jpg|http://www.boldsystems.org/pics/TXEX/slug_5_ventral+1577605440.jpg; Taxon: scientificName: Limaxpseudocinereoniger; phylum: Mollusca; class: Gastropoda; order: Stylommatophora; family: Limacidae; genus: Limax; specificEpithet: pseudocinereoniger; Location: country: Montenegro; locality: Arapova Pećina; decimalLatitude: 43.0481; decimalLongitude: 19.0793; Identification: identifiedBy: Menno Schilthuizen; Record Level: institutionCode: Taxon Expeditions B.V.; basisOfRecord: PreservedSpecimenType status:Paratype. Occurrence: occurrenceDetails: http://www.boldsystems.org/index.php/API_Public/specimen?ids=TxExDU0122|TxExPR0004|TxExDU0041|TxExDU0112|TxExDU0121; recordNumber: TxExDu0121; recordedBy: Rick de Vries; individualID: TxExDU0121; individualCount: 1; sex: H; associatedMedia: http://www.boldsystems.org/pics/TXEX/slug_7+1577602879.jpg|http://www.boldsystems.org/pics/TXEX/slug_7_lateral+1577605850.jpg|http://www.boldsystems.org/pics/TXEX/DU0121ventral+1577614992.jpg|http://www.boldsystems.org/pics/TXEX/slug_7_dorsal+1577605804.jpg|http://www.boldsystems.org/pics/TXEX/DU0121dorsal+1577614812.jpg|http://www.boldsystems.org/pics/TXEX/DU0121lateral+1577614952.jpg|http://www.boldsystems.org/pics/TXEX/slug_7_ventral+1577605892.jpg; Taxon: scientificName: Limaxpseudocinereoniger; phylum: Mollusca; class: Gastropoda; order: Stylommatophora; family: Limacidae; genus: Limax; specificEpithet: pseudocinereoniger; Location: country: Montenegro; decimalLatitude: 43.2189; decimalLongitude: 19.1759; Identification: identifiedBy: Menno Schilthuizen; Record Level: institutionCode: Taxon Expeditions B.V.; basisOfRecord: PreservedSpecimenType status:Paratype. Occurrence: occurrenceDetails: http://www.boldsystems.org/index.php/API_Public/specimen?ids=TxExDU0122|TxExPR0004|TxExDU0041|TxExDU0112|TxExDU0121; recordNumber: TxExPr0004; recordedBy: M. Schilthuizen & I. Njunjić; individualID: TxExPR0004; individualCount: 1; sex: H; associatedMedia: http://www.boldsystems.org/pics/TXEX/TxExPR0004vent+1577624611.JPG|http://www.boldsystems.org/pics/TXEX/TxExPR0004dors+1577624546.JPG|http://www.boldsystems.org/pics/TXEX/TxExPR0004late+1577624578.JPG; Taxon: scientificName: Limaxpseudocinereoniger; phylum: Mollusca; class: Gastropoda; order: Stylommatophora; family: Limacidae; genus: Limax; specificEpithet: pseudocinereoniger; Location: country: Montenegro; locality: Katun Zastan; decimalLatitude: 42.5203; decimalLongitude: 19.7855; Identification: identifiedBy: Menno Schilthuizen; Record Level: institutionCode: Taxon Expeditions B.V.; basisOfRecord: PreservedSpecimenHolotype: Montenegro, Durmitor National Park, Tara Canyon, 43.21888°N, 19.17588°E, 783 m elev., under rocky overhang, 13 July 2018, locality code: TxEx-DU0041, leg. I. Njunjić & Taxon Expedition participants, 1 adult (dissected and DNA-barcoded): RMNH.MOL.338775 in RMNH, Naturalis Biodiversity Center, Leiden, the Netherlands.Paratypes: Montenegro, Durmitor National Park, Sušićko Valley, 43.16900°N; 18.99900°E, 1210 m elev., behind loose bark of log, 13 July 2019, locality code: TxEx-DU0122, leg. M. Schilthuizen & Taxon Expedition participants, 1 adult (dissected and DNA-barcoded) in TXEX, Leiden, The Netherlands. Montenegro, Grabovica, 43.04809°N; 19.07934°E, 1564 m elev., under log, 5 July 2019, locality code: TxEx-DU0112, leg. M. Schilthuizen & I. Njunjić, 1 adult (dissected and DNA-barcoded) in TXEX, Leiden, The Netherlands. Montenegro, Durmitor National Park, Tara Canyon, 43.21888°N, 19.17588°E, 783 m elev., in crevice in rock, 12 July 201), locality code: TxEx-DU0121, leg. R de Vries & Taxon Expedition participants, 1 adult (dissected and DNA-barcoded) in TXEX, Leiden, The Netherlands. Montenegro, Prokletije, Katun Zastan, 42.52031°N, 19.78551°E, 1296 m elev., 24 July 2019, leg. M. Schilthuizen & I. Njunjić, 1 adult (DNA-barcoded) in SNSB-ZSM.Other material. Montenegro, Biogradska Gora (BNM 060820); Bulgaria, Vitosha-Rila-Rhodopes . External appearance.Large, up to 116 mm long; mantle length up to 37 mm; keel length up to 44 mm . Keel prominent. Colouration monochrome or patterned. Body colour dark brown to black, fading to light brown on the flanks or uniformly light brown . Dorsum often darker than the flanks. Keel often  distinctly brighter than the rest of the dorsal body colour. Mantle colour similar to or darker than the dorsum, always without any patterning (preserved specimens have the mantle similar or lighter than the rest of the dorsum). Inner field of the tripartite sole of the foot always creamy white, outer fields mottled grey or black, fading from posterior to anterior and from the outer edge towards the inner field (similar colouration in preserved specimens). Head colour similar to or lighter than the body, darker dorsally than laterally, sometimes with spotted pattern around the mouth area and on the tentacles. Eye tentacles dark grey to black or creamy white with dark pigmented spots (similar colouration in preserved specimens).Genitalia.  See Figs Copulation.Limax , but instead hang from a mucus spot or mucus 'sail'.Mating behaviour is important for species distinction in Limax . Like L.DNA barcode.The COI barcode of the holotype specimen (BOLD registration code TXEX041-19) is given below. Due to the low quality, we trimmed the 5' and 3' ends by 33 and 50 nucleotides, respectively. However, full DNA barcodes are available in BOLD for the paratypes.5'TATAGTAGGAACAGGTTTATCTTTATTAATTCGGTTAGAGTTGGGAACAGCGGGCGTTTTAATAGATGATCACTTTT TTAATGTGATTGTAACTGCTCATGCATTTGTTATAATTTTTTTTATAGTAATACCAATTATGATTGGAGGTTTTGGTAATT GAATGGTTCCACTATTAATTGGAGCTCCCGATATAAGATTTCCTCGAATAAACAATATAAGGTTTTGATTATTACCACCT TCTTTTATTTTACTTATTTGTTCTAGTATGGTAGAGGGTGGTGCAGGTACAGGGTGAACTGTATATCCACCTTTAAGGG GACCTTTAGGTCATGGGGGAGCTTCTGTAGATTTAGCTATTTTTTCATTGCATTTAGCTGGGATGTCTTCTATTTTAGG GGCTATTAATTTTATTACAACTATTTTTAACATACGAACGTCAGGGATAACTATAGAACGTGTGAGGTTATTTGTTTGG TCTATTTTAGTAACTGTTTTTCTACTTTTGTTATCTCTTCCTGTATTAGCAGGGGCAATTACTATACTTTTAACAGATCG TAATTTTAATACTAGGT3'L.pseudocinereoniger is very similar to L.cinereoniger, also in its variability in colour and colour pattern. Based on our own observations, as well as those in L.cinereoniger, but otherwise no consistent external distinguishing marks could be discovered. Besides the nearly 10% differentiation in COI-sequence, a few subtle marks of distinction between the two taxa were found in the genitalia. We have listed these below, with indications on whether the distinguishing characters may be generally or only locally applicable.In external appearance  the one-sided bulge of thickened penis wall of L.cinereoniger specimens that we studied, it is absent or very inconspicuous. However, L.cinereoniger from other localities in which the longitudinal interior penial cord is as well-developed as in L.pseudocinereoniger. It may, therefore, well be a distinction that only applies to the Montenegrin region of sympatry.(ii) the short longitudinal interior penial cord is distinct, whereas in the sympatric Montenegrin L.pseudocinereoniger is highest in its proximal half, whereas in the sympatric Montenegrin L.cinereoniger, it is highest in its distal half. We cannot observe this character in the dissections published by L.cinereoniger range, so it may well be a distinction that only applies to the Montenegrin region of sympatry.(iii) the longitudinal interior penial crest in pseudocinereoniger refers to its similarity with L.cinereoniger. This name was first applied as a "working name" by The specific epithet Limaxpseudocinereoniger Schilthuizen et al., 2022, provided the full citation of this publication appears in the bibliography or elsewhere in the referring work.The taxonomic authority for this species is attributed to all authors of this publication. In line with ICZN Recommendation 51C , the speL.cinereoniger or L.cf.cinereoniger , as well as two specimens from the Tara Canyon (TxExDU0040) in Durmitor National Park, indeed form a relatively cohesive molecular clade which appears to represent a single species, L.cinereoniger. All specimens from Bulgaria and Montenegro identified in pseudocinereonigerL. '', together with five specimens collected in Durmitor National Park and in the Prokletije Mountains in Montenegro  form a different, genetically uniform clade with a genetic distance of ca. 10% from L.cinereoniger. Since this degree of divergence is similar to the differentiation seen amongst other species in Limax .Our phylogenetic analysis Fig.  reveals stetteri  and sincL.cinereonigervar.schulzei Gerhardt, 1941, from the Rila Mountain Range in Bulgaria should be considered a species inquirenda. This taxon, which Gerhardt considered to differ in colouration , anatomy (shorter caecum) and mating behaviour (copulation shorter and earlier in the day) was synonymised with L.cinereonigers. str. by schulzei has not been in use since. The type specimens must be considered lost . However, given the description and the type locality, it is conceivable that the material used by Gerhardt to describe his var. schulzei is conspecific with L.pseudocinereoniger.L.pseudocinereoniger differs from Clades 26, 27 and 28 , brighter colour between the body's external wrinkles (uniform dark grey in L.pseudocinereoniger) and a short, inconspicuous keel .Clade 26 has a penis that is 1.2 times as long as the body length (0.8 times in L.pseudocinereoniger), a penis that is nearly straight (coiled and folded in L.pseudocinereoniger), a completely pale sole (outer fields dark grey in L.pseudocinereoniger) and a short, inconspicuous keel .Clade 27 has a penis that is 0.5 times as long as the body length  and a short, inconspicuous keel .Clade 28 has a mantle colour pattern consisting of some black dots and many white dots and a body pattern of two longitudinal rows of black dots, whereas L.pseudocinereoniger appears to occur sympatrically with L.cinereoniger: the locations TxExDU0040 (L.cinereoniger) and TxExDU0041 (L.pseudocinereoniger), both in the bottom of the Tara Canyon, are located less than 7 km apart.At least in the part of Montenegro that we studied,


Rhodotritoma Arrow, 1925  includes 12 known species worldwide, including three species distributed in China. In the last four decades, no work was conducted on Rhodotritoma in China. In this paper, we review the taxonomy of this genus for Chinese fauna and redescribe a newly-recorded species in China.The genus Rhodotritomamanipurica Arrow, 1925 is recorded from China for the first time. The morphological characters of the adult are redescribed in detail and illustrated. A key to species of the genus Rhodotritoma Arrow, 1925 in China is provided. Chinese specimens were collected from Tibet Autonomous Region and Yunnan Province, which were then deposited in the Museum of Hebei University. The holotype examined is kept in the Natural History Museum. Rhodotritoma was described by Triplaxcoccinea Crotch, 1876, a species distributed in China, India and Burma ; R.cocc6 (China  and Fuji6 (China ) and R.a (Taiwan ).Rhodotritomamanipurica Arrow, 1925 from Tibet and Yunnan was found. Before this study, the species was known only from Assam, India  solution (5%) for five minutes and then cleaned with distilled water. Morphological characters were observed and illustrated with a Nikon SMZ800N stereomicroscope and modified with Adobe Photoshop CS6.0. Habitus photographs were taken with an Olympus E-M5Ⅱ camera. The species has sexual dimorphism. Males can be distinguished by the inner odontoid processes of the pro- and mesofemora. Two males and two females were dissected. Morphological terminology for external structures follows Lawrence .We examined the holotype specimen deposited in the Natural History Museum (NHML) and compared the specimens from China with the holotype in morphological characteristics.Arrow, 1925F8337C98-F40A-5B59-AC83-7DF5C68F3FB7RhodotritomaTriplaxcoccinea Crotch, 1876. Arrow, 1925 - Parts of the following characters combined the features from Body oval, dorsally convex in lateral view. Head with a pair of stridulatory files on occipital region, both sides with ridge processes, anterior part of frons shallowly impressed at each side. Clypeus with anterior border feebly emarginate. Antennae slender, antennomere Ⅱ short, antennomere Ⅲ more than twice as long as wide, antennomeres Ⅵ-Ⅷ slender, antennal club composed of last three antennomeres loosely articulated. Eyes small, finely faceted, interocular distance wide. Terminal maxillary palpomere more than three times as wide as long. Ligula narrow, the middle of front margin slightly emarginated. Labial palpus short, with the terminal palpomere semi-circular. Mentum slightly longer than width. Anterior margin of pronotum with translucent membranous areas, lateral and basal margins with narrow and complete marginal border. Well-marked punctations on anterior and posterior angles. Prosternum flat, narrowed between procoxal cavities, then broadening behind the coxa. Metaventrite process narrow. All the coxal lines absent.Compared to female, male has longer antennae, stronger legs and wider tarsi. In some species, inner edge of the male femur has two small rows of nodules or odontoid processes.Arrow, 1925AF4A8730-1443-5E1C-A6DF-773A2CBAD281Rhodotritomamanipurica Arrow, 1925 - Type status:Holotype. Occurrence: recordedBy: W. Doherty; individualCount: 1; Location: country: India; verbatimLocality: Assam, Manipur; Identification: identifiedBy: G.J. Arrow; Record Level: institutionCode: NHMLType status:Other material. Occurrence: recordedBy: Liang Tang; individualCount: 10; sex: 8 males, 2 females; Location: country: China; stateProvince: Tibet Autonomous Region; county: Milin County [米林县]; verbatimCoordinates: 29.2184°N, 94.1849°E; Event: year: 2005; month: 8Type status:Other material. Occurrence: recordedBy: Xiujuan Yang; individualCount: 1; sex: 1 female; Location: country: China; stateProvince: Yunnan; county: Lushui County, Pianma Town [泸水县，片马镇]; verbatimCoordinates: 26.0078°N, 98.6146°E; Event: year: 2004; month: 5Body elongate-oval, convex dorsally, smooth and shining. General colour orange-yellow, the front edge of clypeus, legs and antenna black Fig. . Head Fa small, Pronotum Fig. f nearly Prosternum Fig. g with teLegs Fig. i slenderMale genitalia Fig. j with meBody length: 4.5-6.0 mm; width: 2.0-4.0 mm.China ; India (Assam).


Translational Psychiatry 10.1038/s41398-022-02267-4, published online 06 December 2022Correction to: The original version of this article unfortunately contained a mistake in an author name. Rudulovic, J. should be Radulovic, J. The original article has been corrected.


NORTH AMERICA28‐29 January 2023International Conference on Wearable Biomedical Sensors and Devices (ICWBSD)New York, USAwww.waset.org26‐30 April 2023Symposium on Advanced Wound Care (SAWC) Spring 2023National Harbour, MD, USAEUROPE21‐22 January 2023International Conference on Advances in Wound Healing Systems (ICAWHS)Amsterdam, Netherlandswww.waset.org/conferences-in-january-2023-in-amsterdam/program23‐24 January 202310th International Congress on Infectious DiseasesBarcelona, Spainwww.conferenceseries.com/infectious-diseases-meetings2‐3 February 2023Norwegian Wound Care SocietyOslo, Norwaywww.nifs-saar.no/oslo-2023April 18, 2023WCS Wound Congress 2023Utrecht, The Netherlandswww.wcs.nl/congres/wcs-wondcongres-2023INTERNATIONAL11‐12 January 2023International Conference on Wound Care and Wound Management (ICWCWM)Singapore, Singaporehttps://waset.org23‐24 February 2023th World Congress on Wound Healing and Critical Care7Dubai, United Arab Emirateswww.aast.org25‐26 March 2023International Conference on Wound Healing Systems and Technologies (ICWHST)Tokyo, Japanwww.waset.org


Correction to: European Journal of Nuclear Medicine and Molecular Imaging10.1007/s00259-021-05513-xThe author regret that the author names for reference 27 of the original article are incorrectly formatted. The correct format appears below:C Nioche, F Orlhac, S Boughdad, S Reuzé, J Goya-Outi, C Robert, C Pellot-Barakat, M Soussan, F Frouin, and I Buvat. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Research 2018; 78(16):4786–4789.


Sweltsa is a genus of green stoneflies in the family Chloroperlidae and is distributed throughout the Nearctic and East Palaearctic Regions. As they are sensitive to pollutants, they are often used as an indicator species for determining the quality of water bodies. There are around 57 species of this genus worldwide and 11 of those have been identified from China.Alloperlini genus Sweltsa Ricker, 1943, Sweltsaligula Rehman, Huo & Du sp. n. is described from Kuankuoshui National Natural Reserve, Suiyang County, Guizhou Province, southwest China. This is the first report of the family Chloroperlidae from Guizhou Province. Diagnosis, description of male, female and nymph, illustration of terminalia and similarities with closely-related species are provided and discussed.A new species of the  Chloroperlidae Okamoto, 1912, a member of the superfamily Perloidea, contains only two subfamilies: Chloroperlinae Okamoto, 1912 and Paraperlinae Ricker, 1943. In China, six genera of Chloroperlidae are presently recorded: Alloperla Banks, 1906, Alaskaperla Stewart & DeWalt 1991, Haploperla Navás, 1934, Suwallia Ricker, 1943, Utaperla Ricker, 1952 and Sweltsa Ricker, 1943 , Jiangsu Province, China. The morphological terminology of Rehman, Huo & Dusp. n.0EE14131-FF03-5450-94FB-1794D6F08C6A95A4A52C-B1A5-44A7-BB3C-3D98BEC3BA07Type status:Holotype. Occurrence: recordedBy: Du Yu-Zhou, Huo Qing-Bo; Yuan Jia-wen; individualID: Insect collection of Yangzhou University (ICYZU), Jiangsu Province, China; individualCount: 1; sex: 1 males; lifeStage: Adult; Taxon: scientificName: Sweltsaligula; kingdom: Animalia; phylum: Arthropoda; class: Insecta; order: Plecoptera; family: Chloroperlidae; genus: Sweltsa; specificEpithet: ligula; taxonRank: Species; Location: continent: Asia; country: China; countryCode: CN; stateProvince: Guizhou; county: Suiyang County; locality: Kuankuoshui National Natural Reserve; verbatimElevation: 1435; verbatimLatitude: 28°13.205′N; verbatimLongitude: 107°9.95′E,; Identification: identifiedBy: Rehman, Huo, Du; Event: year: 2019; month: 5; day: 5; Record Level: language: en; basisOfRecord: PreservedSpecimen.Type status:Paratype. Occurrence: recordedBy: Du Yu-Zhou, Huo Qing-Bo; Yuan Jia-wen; individualID: Insect collection of Yangzhou University (ICYZU), Jiangsu Province, China; individualCount: 7; sex: 1 males, 2 femles; lifeStage: 3 adults, 4 nymphs; Taxon: scientificName: Sweltsaligula; kingdom: Animalia; phylum: Arthropoda; class: Insecta; order: Plecoptera; family: Chloroperlidae; genus: Sweltsa; specificEpithet: ligula; taxonRank: Species; Location: continent: Asia; country: China; countryCode: CN; stateProvince: Guizhou; county: Suiyang County; locality: Kuankuoshui National Natural Reserve; verbatimElevation: 1435; verbatimLatitude: 28°13.205′N; verbatimLongitude: 107°9.95′E,; Identification: identifiedBy: Rehman, Huo, Du; Event: year: 2019; month: 5; day: 5; Record Level: language: en; basisOfRecord: PreservedSpecimen.Adult habitus. Triocellate. General colour greenish in the field, but becoming pale brown in ethanol. The head is also black in the field, but changes to brown in ethanol. Head with rounded pale yellow spot between compound eye and lateral ocellus, frons dark brown from epicranial suture to clypeus and with broad pale areas along lateral margins adjacent to antennal bases. Compound eyes dark greyish, ocelli greyish, anterior ocellus paler with dark black margins; antennae and palpi pale. The pronotum disc is completely brown, bearing symmetrical rugosities, margin dark brown ; forewing length 7.0–7.5 mm, hind-wing length 6.2–6.8 mm. Tergum 9 sclerotised, posteriorly strongly sclerotised bearing long brown hairs, dorsally without any ridge and stripe. Tergum 10 divided medially; the medial portion enlarged, forming a shield-like structure with a dark brown basal anchor ; forewing length 8.0–8.5 mm, hind-wing length 7.0–7.5 mm. Habitus is generally similar to the male. Head and pronotum are darker than the males. Abdominal tergum 1–4 dorsally with median stripe of brown trapezoidal spots and terga 5–7 with median stripe of oval shape Fig. B. SternuUnknownHabitus Fig. A–B. BodyThis new species is characterised by the dark pigmentation of the head, pronotum and the shape of epiproct. Tergum 9 is sclerotised without any ridge and stripe. Epiproct is long and spoon-shaped, apically rounded in dorsal view; in lateral aspect, the epiproct is thin and parallel for its most part, apically wide and slightly curved at the apex.ligula” means spoon shape.The name of the new species refers to the shape of the epiproct that is spoon-shaped. The Latin “China (Guizhou Province).Sweltsacolorata Zhiltzova & Levanidova, 1978 in S.colorata by the head, pronotum pigmentation and the shape of the epiproct. The head and pronotum disc of the new species are highly sclerotised and darker than S.colorata . The adults often emerged under the wide rocks (Fig. The new species is very similar to iew Fig. A–B, whil


Scientific Reports 10.1038/s41598-020-60612-3, published online 26 February 2020Correction to: The original version of this Article contained an error in Reference 39, which was incorrectly given as:Handbook of integrative clinical psychology, psychiatry, and behavioral medicine: perspectives, practices, and research. (2010).Carlstedt, R. A. The correct reference is listed below:Handbook of integrative clinical psychology, psychiatry, and behavioral medicine: perspectives, practices, and research. Chapter 5 title: Behavioral Genetics by Vinkhuyzen AE, van der Sluis S, Posthuma D pp 81-82 (2010).Carlstedt, R. A. The original Article has been corrected.


Scientific Reports 10.1038/s41598-023-28478-3, published online 30 January 2023Correction to: The original version of this Article contained errors. The title of this paper“Assessment of therapeutic role of mesenchymal stromal cells in mouse models of graft-versus-host disease using cryo-imaging”now reads:“Assessment of the therapeutic role of mesenchymal stromal cells in a mouse model of graft-versus-host disease using cryo-imaging”In addition, References 40, 41, 46 and 49 contained errors, where the titles and the DOI of the respective works were omitted.The correct references are listed below:Reference 40:Proceedings of the 2020 4th International Conference on Vision, Image and Signal Processing (ICVISP),Article 6, 1–7. https://doi.org/10.1145/3448823.3448834 (2020).Ketson, P. & Wuttisarnwattana, P. White Pulp Segmentation Algorithm for Mouse Spleen Cryo-imaging Data Using U-Net. Reference 41:Proceedings of the 2016 13th International Conference on Electrical Engineering/Electronics, Computer, Telecommunications and Information Technology (ECTI-CON), 1-5. https://doi.org/10.1109/ECTICon.2016.7561436 (2016).Wuttisarnwattana, P. Automatic whole mouse segmentation for cryo-imaging data using DRLSE model. Reference 46:Proceedings of the 2021 18th International Conference on Electrical Engineering/Electronics, Computer, Telecommunications and Information Technology (ECTI-CON), 650-653. https://doi.org/10.1109/ECTI-CON51831.2021.9454766 (2021).Chatboonward, T. & Wuttisarnwattana, P. Biliary Tract Autofluorescence Cleaning for Liver Cryo-imaging Data. Reference 49:Proceedings of the 2014 SPIE Medical Imaging: Biomedical Applications in Molecular, Structural, and Functional Imaging (SPIE MI),9038, https://doi.org/10.1117/12.2042960 (2014).Wuttisarnwattana, P., Raza, S., Eid, S., Cooke, K. & Wilson, D. Novel T Lymphocyte Proliferation Assessment Using Whole Mouse Cryo-Imaging. The original Article and accompanying Supplementary Information 1 file have been corrected.


Appropriate antifungal treatment is crucial for managing IFI. We evaluated the 1,226 moulds causing IFI  were consecutively collected (1/patient) in 43 worldwide hospitals from 2017-2021 and susceptibility tested by CLSI broth microdilution. CLSI interpretation criteria were applied. Pneumonia was the predominant infection type among ICU (81.6%) and non-ICU (71.8%) patients.Aspergillus spp. was the most common mould (87.6%/80.5%). A. fumigatus , A. section Flavi , and A. section Nigri  were the top 3 Aspergillus groups. ISC inhibited 94.2%/91.2%, 100.0%/98.6%, and 96.0%/96.7% of AFM, ASF, and ASN from ICU/non-ICU, respectively, at the epidemiological cut-off values. Similar activities were noted for ISC, PSC, ITC, and VRC against AFM from ICU  and non-ICU  isolates. No difference in the azole activities was noted against ASF from ICU  and non-ICU  or ASN from ICU  and non-ICU  isolates. VRC-non-susceptible (NS) AFM isolates were detected in 9.3% of ICU and 9.0% of non-ICU isolates. Among VRC-NS AFM from ICU/non-ICU, 58.3%/27.5% were wildtype (WT) to ISC, 50.0%/25.0% were ITC-WT, and 75.0%/50.0% remained VRC-WT, respectively. VRC was the most active azole against Scedosporium spp. (SCE) but was less active against Mucorales (MUC) than the other azoles. All azoles showed limited activity against Fusarium spp. (FUS). No difference on azole activities against SCE, MUC, and FUS were noted from ICU and non-ICU isolates.Aspergillus isolates from ICU and non-ICU, including against VRC-NS AFM from ICU. Azoles displayed similar activity against moulds from ICU and non-ICU units.ISC was active against Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Paul Rhomberg, BS, MT(ASCP), Cidara: Grant/Research Support|Pfizer: Grant/Research Support Paul Rhomberg, BS, MT(ASCP), Cidara: Grant/Research Support|Pfizer: Grant/Research Support Beth A. Schaefer, BA, MT(ASCP), Pfizer: Grant/Research Support Michael A. Pfaller, MD, Pfizer: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support.


Article title: Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolopyrimidine derivatives as CDK inhibitors Authors: Bo Yang, Yanni Quan, Wu-li Zhao, Yingjie Ji, Xiaotang Yang, Jianrui Li, Yi Li, Xiujun Liu, Ying Wang, Yanping Li Journal:Journal of Enzyme Inhibition and Medicinal ChemistryBibliometrics: Volume 38, Number 1 DOI:https://doi.org/10.1080/14756366.2023.21692822 group for compound 2g in The authors would like to point out that the wrong version of


In “Culturally Safe eHealth Interventions With Aboriginal and Torres Strait Islander People: Protocol for a Best Practice Framework” :e34904), the authors noted one error.In the originally published article, Reference 23 incorrectly appeared as follows:Mitchell-Box K, Braun KL. Fathers' thoughts on breastfeeding and implications for a theory-based intervention. J Obstet Gynecol Neonatal Nurs 2012 Nov;41(6):E41-E50. [doi: 10.1111/j.1552-6909.2012.01399.x] [Medline: 22861175]In the corrected version, the correct Reference  has beenCouch D, Doherty Z, Panozzo L, Naren T, Burzacott J, Ward B, et al. The impact of telehealth on patient attendance and revenue within an Aboriginal Community Controlled Health Organisation during COVID-19. Australian Journal for General Practitioners 2021 Nov;50(11):851-855. [doi: 10.31128/AJGP-07-21-6060] [Medline: 34713288]The correction will appear in the online version of the paper on the JMIR Publications website on October 14, 2022, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.


Scientific Reports 10.1038/s41598-022-08708-w, published online 16 March 2022Correction to: The original version of this Article contained an error in Reference 6, which was incorrectly given aset al. Sedation management during therapeutic hypothermia for neonatal encephalopathy: Atropine premedication for endotracheal intubation causes a prolonged increase in heart rate. Resuscitation85, 1394–1398 (2014).Gill, H. The correct reference is listed below:World J Gastroenterol.15, 5838–5842 (2009).Park, S. J., Choi, S. I., Lee, S. H., & Lee, K. Y. Image-guided conservative management of right colonic diverticulitis. Additionally, the Funding section was omitted. The Funding section now reads:“Financial or grant support: The Ministry of Science and Technology, Taiwan (MOST 110-2511-H-002-009-MY2).”The original Article has been corrected.


Anti-S Ab response (conferred by infection and/or vaccination) is more closely associated with protection. We evaluated anti-N/S Ab responses in vaccinated . Baseline, 1, 2, 3, 6, and 12 months, and delivery samples were tested for anti-N (index ≥ 1.4 positive) and anti-S (≥ 50 AU/mL positive) IgG Ab by Abbott Architect. Kaplan-Meier methods were used to measure Ab response duration.Among 78 participants, 62 (79%) enrolled in pregnancy (median 27 weeks gestation), and 16 (21%) at delivery/postpartum (median 2 weeks); 34 (44%) had received ≥1 vaccine prior to initial Ab testing. At baseline, 59 (75%) participants had concordant anti-N/S positive results . Anti-S IgG was higher  among participants receiving ≥1 vaccine vs no vaccine, while anti-N IgG indices were similar.Among 59 participants with initial anti-N IgG+ results, median time to anti-N IgG negative results was 31 weeks after first RT-PCR+ (median 17 weeks after first anti-N IgG+ result). Only 1 (unvaccinated) participant had an anti-S IgG negative result by 22 weeks after first RT-PCR+ result.Among 30 participants with delivery samples , 15 (52%) remained anti-N IgG+; 29 (97%) remained anti-S IgG+. Anti-S IgG was higher  among participants receiving ≥ 1 vaccine vs. no vaccine prior to delivery.Among pregnant persons with prior SARS-CoV-2 infection, duration of anti-S IgG response was longer than anti-N IgG irrespective of vaccine status; vaccination during pregnancy was associated with higher anti-S levels at baseline and delivery. While anti-S IgG were detectable for ≥ 6 months, longer term follow-up is needed to assess durability of hybrid immunity vs. infection alone and has implications for maternal and infant protection.Sylvia M. LaCourse, MD, MPH, Aurum Institute: Advisor/Consultant|Merck: Grant/Research Support Alexander L. Greninger, MD, PhD, Abbott: Contract Testing|Cepheid: Contract Testing|Gilead: Grant/Research Support|Gilead: Contract Testing|Hologic: Contract Testing|Merck: Grant/Research Support|Novavax: Contract Testing|Pfizer: Contract Testing Alisa B. Kachikis, MD, MSc, GSK: Advisor/Consultant|Merck: Grant/Research Support|Pfizer: Advisor/Consultant Janet A. Englund, MD, AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Grant/Research Support|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant Alison L. Drake, PhD, MPH, Merck: Grant/Research Support.


Conidiobolus group belong to the family Ancylistaceae  and include over 70 predominantly saprotrophic species in four similar and closely related genera, that were separated phylogenetically recently. Entomopathogenic fungi of the genus Batkoa are very close morphologically to the Conidiobolus species. Their thalli share similar morphology, and they produce ballistic conidia like closely related entomopathogenic Entomophthoraceae. Ballistic conidia are traditionally considered as an efficient tool in the pathogenic process and an important adaptation to the parasitic lifestyle. Our study aims to reconstruct the phylogeny of this fungal group using molecular and genomic data, ancestral lifestyle and morphological features of the conidiobolus-like group and the direction of their evolution. Based on phylogenetic analysis, some species previously in the family Conidiobolaceae are placed in the new families Capillidiaceae and Neoconidiobolaceae, which each include one genus, and the Conidiobolaceae now includes three genera. Intermediate between the conidiobolus-like groups and Entomophthoraceae, species in the distinct Batkoa clade now belong in the family Batkoaceae. Parasitism evolved several times in the Conidiobolus group and Ancestral State Reconstruction suggests that the evolution of ballistic conidia preceded the evolution of the parasitic lifestyle.Fungi of the  Batkoa major .Type species:Batkoa apiculata (Thaxter) Humber, Mycotaxon 34 (2): 446 (1989), [MB 135576].Entomophthora apiculata (Thaxt.) M.A. Gust., Kungliga Landbruks-Höngskolans Annaler 31: 131 (1965) [MB 330591].=Conidiobolus apiculatus (Thaxt.) Remaud. & S. Keller Mycotaxon 11 (1): 330 (1980) [MB 118560].=Description: Mycelia of hyaline, septate, branching hyphae. Hyphal bodies hypha- or ameboid-like, subglobose to elongate, multinucleate, nuclei staining with aceto-orcein. Primary conidiophores simple, positively phototropic, bearing a single apical primary conidium. Primary conidia forcibly discharged, single-celled, multinucleate, globose, with prominent conical papilla. Replicative conidia similar and smaller than primary conidia. Chlamydospores globose, hyaline. Zygospores globose, hyaline or yellowish. Rhizoids present or absent. Obligate pathogens of insects.Notes: Members of the Batkoaceae are entomopathogenic, infecting insects from various orders, ballistospore-forming fungi with a broad global distribution. Their cultures are easily to isolate on simple culture media. Accepted species:Batkoa amrascae S. Keller & Villac., Philippine Entomologist 11 (1): 81 (1997) [MB 313160].Batkoa apiculata (Thaxt.) Humber, Mycotaxon 34 (2): 446 (1989) [MB 135576].Batkoa cercopidis (S. Keller) B. Huang, Humber & K.T. Hodge, Mycotaxon 100: 231 (2007) [MB 510686].Batkoa dysderci (Viegas) Humber, Mycotaxon 34 (2): 446 (1989) [MB 135577].Batkoa gigantea (S. Keller) Humber, ibid. [MB 135578].Batkoa hydrophila S. Keller, Sydowia 59 (1): 77 (2007) [MB 529508].Batkoa limoniae (S. Keller) S. Keller, Nova Hedwigia 73 (1–2): 171 (2001) [MB 484564]Batkoa major (Thaxter) Humber, Mycotaxon 34 (2): 446 (1989) [MB 135579].Batkoa obscura  Gryganskyi, comb. nov. [MB 844349].Basionym: Entomophthora obscura I.M. Hall & P.H. Dunn, Hilgardia 27: 162 (1957) [MB 297265] = Conidiobolus obscurus  Remaud.; S. Keller, Mycotaxon 11 (1): 331 (1980) [MB 118567].Batkoa papillata (Thaxter) Humber, Mycotaxon 34 (2): 446 (1989) [MB 135580].Batkoa pseudapiculata (S. Keller) B. Huang, Humber & K.T. Hodge, Mycotaxon 100: 231 (2007) [MB 510687].Type genus: Capillidium B. Huang & Y. Nie, MycoKeys 66: 62 (2020)  = Conidiobolus heterosporus Drechsler, Am. J. Botany 40: 107 (1953) [MB 295472]Description: Mycelia hyaline. Primary conidiophores simple, bearing single primary conidia. Primary conidia forcibly discharged, multinucleate, hyaline, globose, pyriform to obovoid. Two kinds of replicative conidia, the first similar and smaller than primary conidia, the second (capilliconidia) arise singly, off-axis at the top of slender, elongate conidiophores, and are not forcibly discharged. Zygospores present or absent, formed in axial alignment with conjugating segments, globose to subglobose, often smooth, sometimes rough, hyaline or yellowish.Accepted species:Capillidium adiaeretum (Drechsler) B. Huang & Y. Nie, MycoKeys 66: 61 (2020) [MB 831602]Capillidium bangalorense (Sriniv. & Thirum.) B. Huang & Y. Nie, ibid. [MB 831607]Capillidium denaeosporum (Drechsler) B. Huang & Y. Nie, ibid. [MB 831608]Capillidium heterosporum (Drechsler) B. Huang & Y. Nie, ibid. [MB 831601]Capillidium jiangsuense B. Huang & Y. Nie, MycoKeys 89: 146 (2022) [MB 842228]Capillidium lobatum (Sriniv. & Thirum.) B. Huang & Y. Nie, MycoKeys 66: 62 (2020) [MB 831609]Capillidium macrocapilliconidium B. Huang & Y. Nie, MycoKeys 89: 143 (2022) [MB 842227]Capillidium pumilum (Drechsler) B. Huang & Y. Nie, MycoKeys 66: 61 (2020) [MB 831610]Capillidium rhysosporum (Drechsler) B. Huang & Y. Nie, ibid. [MB 831611] Capillidium rugosum (Drechsler) B. Huang & Y. Nie, ibid. [MB 842229].Type genus: Conidiobolus Bref., Untersuchungen aus dem Gesamtgebiete der Mykologie 4: 35 (1884) Description: Mycelium of hyaline, septate, branching hyphae. Hyphae multinucleate, with small nuclei that do not stain with aceto-orcein. Simple hyphal conidiogenous cells each develop one apical conidium, a ballistospore that is forcibly discharged by rapid circumcissile rupture and papillar eversion. Detached conidia are hyaline, single-celled, more or less globose, with an everted blunt conical papilla where they were once attached to the conidiophore. Sexual zygospores, present or absent, formed in axial alignment with conjugating segments, globose to subglobose.Notes: Members of the Conidiobolaceae are saprobic, ballistospore-forming fungi with a broad global distribution. They grow readily on simple culture media, typically as white to cream colonies, often forming satellite colonies derived from the asexual ballistospores. The primary ballistospores may germinate in three ways: to form a smaller ballistospore of similar form as the parent spore, to form a passively dispersed capilliconidium atop a long, attenuated stalk, or they may form a hyphal germ tube. Some species are able to opportunistically infect humans and other animals.Conidiobolaceae B. Huang, Stajich & K.T. HodgeIncluded genera (3) and species:Azygosporus B. Huang & Y. Nie, MycoKeys 85: 165 (2021) [MB 840849]Accepted species:Azygosporus macropappilatus B. Huang & Y. Nie, ibid. [MB 840848]Azygosporus parvus (Drechsler) B. Huang & Y. Nie, ibid. [MB 840850]Conidiobolus sensu stricto according to B. Huang & Y. Nie 2020 [MB 20144]Accepted species:Conidiobolus coronatus (Costantin) Batko, Entomophaga 2: 129 (1964) [MB 283037]Conidiobolus bifurcatus B. Huang & Y. Nie, MycoKeys 73: 137 (2021) [MB 831599]Conidiobolus brefeldianus Couch, American Journal of Botany 26: 119 (1939) [MB 258852]Conidiobolus dabieshanensis Y. Nie & B. Huang, Mycosphere 8 (7): 811 (2017) [MB 552756]Conidiobolus gonimodes Drechsler, Mycologia 53: 292 (1961) [MB 328751]Conidiobolus iuxtagenitus S.D. Waters & Callaghan, Mycological Research 93 (2): 223 (1989) [MB 135617]Conidiobolus khandalensis Sriniv. & Thirum., Mycologia 54 (6): 692 (1963) [MB 328754]Conidiobolus lichenicola Sriniv. & Thirum., Mycopathologia et Mycologia Applicata 36: 344 (1968) [MB 328755]Conidiobolus lunulus D. Goffre, R.A. Humber & P.J. Folgarait, Mycologia: 131 (1): 56 (2020) [MB 834443] should be in this group by morphology.Conidiobolus macrosporus Sriniv. & Thirum., Mycologia 59: 702 (1967) [MB 328757]Conidiobolus mycophagus Sriniv. & Thirum., Sydowia 19 (1–6): 88 (1965) [MB 328759]Conidiobolus mycophilus Sriniv. & Thirum., ibid. [MB 328760]Conidiobolus polyspermus Drechsler, Mycologia 53: 279 (1961) [MB 328763]Conidiobolus polytocus Drechsler, American Journal of Botany 42: 793 (1955) [MB 295480]Conidiobolus taihushanensis B. Huang & Y. Nie, MycoKeys 73: 140 (2021) [MB 835124]Conidiobolusutriculosus Bref., Untersuchungen aus dem Gesamtgebiete der Mykologie 4: 35 (1884) [MB 144259] HOLOTYPE SPECIESConidiobolus variabilis B. Huang & Y. Nie, MycoKeys 73: 142 (2021) [MB 835125]C. chlamydosporus, C. firmipileus, C. humicolus, C. incongruous and C. megalotocus.Additional species to be considered: Microconidiobolus B. Huang & Y. Nie, MycoKeys 66: 72 (2020) [MB 831597]Accepted species:Microconidiobolus nodosus (Sriniv. & Thirum.) B. Huang & Y. Nie, ibid. [MB 831624]Microconidiobolus paulus (Drechsler) B. Huang & Y. Nie, ibid. [MB 831605]Microconidiobolus terrestris (Sriniv. & Thirum.) B. Huang & Y. Nie, ibid. [MB 831625]Microconidiobolus undulatus.Additional species to be considered: Type genus: Neoconidiobolus B. Huang & Y. Nie, MycoKeys 66: 70 (2020) [MB 831598]Type species:Neoconidiobolus thromboides (Drechsler) B. Huang & Y. Nie, MycoKeys 66: 70 (2020) [MB 831606] = Conidiobolus thromboides Drechsler, J. Washington Acad. Sci. 43: 38 (1953) [MB 295484]Description: Mycelia hyaline. Primary conidiophores are simple or sometimes branched, positively phototropic, bearing a single apical primary conidium. Primary conidia forcibly discharged, multinucleate, hyaline, globose, pyriform to obovoid. Replicative conidia similar and smaller than primary conidia. Chlamydospores globose, formed terminally on hyphae or from globose cells by thickening of the wall. Zygospores formed in axial alignment with two conjugating segments, globose to ellipsoidal, smooth, hyaline, rarely pale yellowish.Notes: Species of the family Neoconidiobolaceae resemble those of the Conidiobolaceae in lacking both microconidia and capilliconidia. All members in the clade of Neoconidiobolus share the following characteristics: forcibly discharged, hyaline, globose, pyriform to obovoid primary conidia. Two kinds of replicative conidia are produced: One is discharged, similar to and smaller than primary conidia; the other is elongate and forcibly discharged. Two types of resting spores are produced: zygospores and chlamydospores.Accepted species:Neoconidiobolus couchii (Sriniv. & Thirum.) B. Huang & Y. Nie, MycoKeys 66: 73 (2020) [MB 831626]Neoconidiobolus kunyushanensis B. Huang & Y. Nie, Mycological Progress 20: 1233 (2021) [MB 831600]Neoconidiobolus lachnodes (Drechsler) B. Huang & Y. Nie, MycoKeys 66: 73 (2020) [MB 831627]Neoconidiobolus mirabilis (Y. Nie & B. Huang) B. Huang & Y. Nie, ibid. [MB 831628]Neoconidiobolus osmodes (Drechsler) B. Huang & Y. Nie, ibid. [MB 831629]Neoconidiobolus pachyzygosporus (Y. Nie & B. Huang) B. Huang & Y. Nie, ibid. [MB 831630]Neoconidiobolus sinensis  B. Huang & Y. Nie, ibid. [MB 831631]Neoconidiobolus stilbeus (Y. Nie & B. Huang) B. Huang & Y. Nie, ibid. [MB 831632]Neoconidiobolus stromoideus (Sriniv. & Thirum.) B. Huang & Y. Nie, ibid. [MB 831633]Neoconidiobolus thromboides (Drechsler) B. Huang & Y. Nie, ibid. [MB 831606]Neoconidiobolus vermicola (J.S. McCulloch) B. Huang & Y. Nie, ibid. [MB 831634]Azygosporus, Conidiobolus, Capillidium, Microconidiobolus and Neoconidiobolus. The ability to infect insects was developed in various groups and multiple times during the evolution of these fungi. Of the 18 species included in the Conidiobolaceae, C. macrosporus is host specific pathogen. Of the 11 species included in Neoconidiobolus, two are pathogens with broader host ranges (Neoconidiobolus osmodes and Neoconidiobolus thromboides). None of the species included in Capillidiaceae (three Microconidiobolus and six Capillidium) are pathogens. Also, ancestors of the entomophthoralean fungi became entomopathogenic and didn’t lose this ability further on; all extant members of this group (families Batkoaceae and Entomophthoraceae) are entomopathogenic (The ancestors of entomophthoralean fungi were with high probability saprotrophic, as with most of their extant basal lineages thogenic . A similar evolutionary trajectory was reconstructed for another character—ballistic conidia. This character evolved very early in Entomophthoromycotina, in the ancestors with saprotrophic lifestyles, possibly as an adaptation for spore dissemination , and thiPhylogenetic reconstruction suggests polyphyletic origins of conidiobolus-like fungi, and not a single origin. The polyphyletic origin of this composite fungal group was already suggested by our previous works ,22,23,24Conidiobolus and Microconidiobolus were grouped together, while on our tree they are located separately. Therefore, we haven’t assigned a corresponding unique taxonomic level to Microconidiobolus that is higher than genus, as we do not yet have genomic or transcriptomic data. Species of Microconidiobolus differ morphologically in producing microconidia and this is not characteristic of other members of the Conidiobolaceae. Taxonomic level needs more taxa and more genomes involved for phylogenetic reconstruction.There are some differences in the placement of certain groups and taxa. In the study of Nie et al. , the genMassospora and two species of Entomophthora together in one clade is caused by the lack of the genes for both Entomophthora species. Their missing data might cause some interference with better gene sampling for Massospora. In any case, Massospora is next to Entomophthora, as in most previous phylogenetic reconstructions. Also, there are some discrepancies inside the family Entomophthoraceae. The issue with having Neoconidiobolus thromboides appears in our phylogenetic reconstruction not as a single clade. This might be an indication that this taxon represents a species complex or group of species, and reflects the diversity of this fungal group, which is similar to another complex species, Conidiobolus coronatus. The resolution of these two species complexes possibly containing several cryptic species needs better genome sampling. The presence of Neoconidiobolus heterosporus inside it can provide a hint. In any case, the spore sizes and especially hosts and substrates of Neoconidiobolus thromboides are definitely worth studying in more detail with support from genome references.Azygosporus, Capillidium, Micro-, Neo- and Conidiobolus isolates. Only a few species of Entomophthoraceae grow well under laboratory conditions in pure culture, mostly requiring special nutritive media, and the majority of species in this fungal lineage are not yet culturable [Conidiobolus group range from 25 to 90 Mb and this is rather more typical for the saprotrophs and insect symbionts in terrestrial fungal lineages [The division of Entomophthoromycotina reflects the gradual evolutionary switch from saprotrophy to the parasitic lifestyle, with multiple origins. While all Entomophthoraceae are insect pathogens, conidiobolus-like fungi occupy more diverse ecological niches. They developed the adaptation of infecting insects several times during their evolution. The family Batkoaceae presents intermediate placement between these two groups. While all known species in the Batkoaceae are insect pathogens, they are easy to culture on artificial nutrient media like lturable . TypicalSimilarly to the parasitism of insects, parasitism of other groups of living organisms like lichens, nematodes, and mushrooms developed independently several times in different branches among saprotrophic conidiobolus-like fungi over their evolutionary trajectories. Ancestral state reconstruction for lifestyle and ballistic conidia appearance suggests that these two features coexisted for a long-time during evolution, and ballistic conidia were present in the early ancestors of the whole group already, before pathogenic lifestyles were adopted. Ballistic conidiospores were already present at the very beginning of Entomophthorales evolution in saprotrophic lineages. Although ballistic conidia were described as a hallmark of entomopathogens, they could not be an adaptation to the parasitic lifestyle, namely an adaptation to infect insects. However, the ability of these fungi to eject spores for significant distances, possibly along with light sensing mechanisms, and involving attachment to the substrate due to conidiophore content , essentiOur study aims to add some structure to the very unclear taxonomic positioning of conidiobolus-like fungi. Despite many morphological similarities, they have polyphyletic origins and occupy various econiches ranging from saprotrophy to entomopathogenicity. We hope that our study will help the researchers of this fungal group to assess relatedness between these families and with the entomopathogenic Entomophthoraceae, and also predict the ecological niches of new species of these families, as further discoveries continue.


Correction: Orphanet Journal of Rare Diseases (2022) 17:443https://doi.org/10.1186/s13023-022-02488-2Following publication of the original article , we haveDGS (Forward and Reverse)Also, reference 40 should be as follows:40. Quinn J, Georgiadis A, Lewis HB, Jurecki E. Measuring burden of illness in phenylketonuria (PKU): development of the PKU symptom severity and impacts scale as a robust patient-reported outcome. Adv Ther. 2022;39:971–91.


Simuliidae from India is presented. A total of 79 species of Simulium belonging to eight different subgenera are listed. Eleven species that were not reported in the previous checklist are added here. The present list contributes to a better understanding of the diversity of Simuliidae in India, as well as the impact of Simulium species on the public health of this mega-diverse country.An updated checklist of the family  Diptera, Nematocera, Simuliidae) are infamous as vectors for transmitting onchocerciasis (river blindness) in many countries throughout the world (Simuliidae was first published by Crosskey (1988) and has since been updated almost every year. The beginning of simuliid research was in the early 19th century when SimuliumLatreille, 1802. The family Simuliidae Newman, 1834 was established by Simulium. According to Simulium from India was probably by th century, the simuliid research was mainly undertaken by Datta  aureum Fries, 18241. Simulium (Eusimulium) weiningense Chen & Zhang, 19972. Simulium (Gomphostilbia) bucolicum Datta, 19753. Simulium (Gomphostilbia) darjeelingense Datta, 19734. Simulium (Gomphostilbia) fidum Datta, 19755. Simulium (Gomphostilbia) litoreum Datta, 19756. Simulium (Gomphostilbia) metatarsale Brunetti, 19117. Simulium (Gomphostilbia) pattoni Senior-White, 19228. Simulium (Gomphostilbia) sundaicum Edwards, 19349. Simulium (Gomphostilbia) tenuistylum Datta, 197310. Simulium (Gomphostilbia) unum Datta, 197511. 23°14'28.7"N, 87°3'42.6"E and 23°19'57.1"N, 86°21'46.8"E) in West Bengal, India. It was not included in In the revised inventory of Simulium (Gomphostilbia) agasthyamalaiense Vijayan, Anbalagan, Rekha, Dinakaran & Krishnan, 201912. 8°55'4.1"N, 77°36'1.6"E), India.This species was described by Simulium (Gomphostilbia) barnesi Takaoka & Suzuki, 198413. Simulium (Gomphostilbia) cauveryense Anbalagan, 201514. Simulium (Gomphostilbia) decuplum Takaoka & Davies, 199515. Simulium (Gomphostilbia) dinakarani Anbalagan, 202016. 10°27'30.7"N, 78°01'15.7"E), India.This species was described by Simulium (Gomphostilbia) kottoorense Anbalagan, 201517. Simulium (Gomphostilbia) krishnani Anbalagan, 202018. 14°58'36"N, 74°46'40"E), India, by This species was reported from Karnataka (Simulium (Gomphostilbia) kumbakkaraiense Anbalagan, 201919. Simulium (Gomphostilbia) panagudiense Anbalagan 201520. 10°18'30.3"N, 77°53'35.8"E), India.This species was recently described by Simulium (Gomphostilbia) parahiyangum Takaoka & Sigit, 199221. Simulium (Gomphostilbia) peteri Anbalagan, 201422. Simulium (Gomphostilbia) sachini Takaoka & Henry, 201023. Simulium (Gomphostilbia) takaokai Anbalagan, 201424. Simulium (Gomphostilbia) williei Takaoka & Thapa, 201025. Simulium (Montisimulium) dasguptai Datta, 197426. Simulium (Montisimulium) dattai Takaoka & Somboon, 200827. Simulium (Montisimulium) ghoomense Dutta, 197328. Simulium (Montisimulium) nemorivagum Datta, 197329. Simulium (Montisimulium) yuntaiense Chen, Wen & Wei, 200630. Simulium (Nevermannia) aureohirtum Brunetti, 191131. Simulium (Nevermannia) gracilis Datta, 197332. Simulium (Nevermannia) karavalliense Anbalagan, Rekha, Vijayan, Balachandran, Dinakaran & Krishnan, 202033. 11°20'03.8"N, 78°19'19.6"E), India and described by This species was reared from pupae collected in Tamil Nadu (Simulium (Nevermannia) praelargum Datta, 197334. Simulium (Nevermannia) purii Datta, 197335. Simulium (Nevermannia) rufithorax Brunetti, 191136. Simulium (Nevermannia) senile Brunetti, 191137. Simulium (Nevermannia) subratai Takaoka, Thapa & Henry, 201138. Simulium (Nevermannia) wichaii Takaoka, 201039. Simulium (Tetisimulium) stevensoni Edwards, 192740. Simulium  indicum Becher, 188541. Simulium (Simulium) alajense Rubtsov, 193842. Simulium (Simulium) asishi Datta, 198543. Simulium (Simulium) adventicium Datta, 198544. Simulium (Simulium) barraudi Puri, 193245. Simulium (Simulium) biforaminiferum Datta, 197446. Simulium (Simulium) consimile Puri, 193247. Simulium (Simulium) christophersi Puri, 193248. Simulium (Simulium) dentatum Puri, 193249. Simulium (Simulium) digitatum Puri, 193250. Simulium (Simulium) ephemerophilum Rubstov, 194751. Simulium (Simulium) gravelyi Puri, 193352. Simulium (Simulium) griseifrons Brunetti, 191153. Simulium (Simulium) grisescens Brunetti, 191154. Simulium (Simulium) gurneyae Senior-White, 192255. Simulium (Simulium) himalayense Puri, 193256. Simulium (Simulium) hirtipannus Puri, 193257. Simulium (Simulium) howletti Puri, 193258. Simulium (Simulium) kapuri Datta, 197559. Simulium (Simulium) lineothorax Puri, 193260. Simulium (Simulium) nigrifacies Datta, 197461. Simulium (Simulium) nilgiricum Puri, 193262. Simulium (Simulium) nitidithorax Puri, 193263. Simulium (Simulium) novolineatum Puri, 193364. Simulium (Simulium) nodosum Puri, 193365. Simulium (Simulium) pallidum Puri, 193266. Simulium (Simulium) palmatum Puri, 193267. Simulium (Simulium) palniense Puri, 193268. Simulium (Simulium) pradyai Takaoka & Somboon, 200869. Simulium (Simulium) pothigaiense Anbalagan, 201870. Simulium (Simulium) ramosum Puri, 193271. Simulium (Simulium) rashidi Lewis, 197372. Simulium (Simulium) rufibasis Brunetti, 191173. Simulium (Simulium) singtamense Datta & Pal, 197574. Simulium (Simulium) striatum Brunetti, 191275. Simulium (Simulium) tenuitarsus Puri, 193376. Simulium (Simulium) valparaiense Anbalagan, 201877. Simulium (Simulium) yanaense Anbalagan, 201978. 14°31'19.2"N, 74°19'12"E), India by This species was described from Karnataka (Simulium (Wilhelmia) pseudequinum Séguy, 192179.


Dalbavancin , a long-acting lipoglycopeptide approved by the US FDA and EMA for acute bacterial skin and skin structure infections (ABSSSI) has potent activity against Gram-positive pathogens including MRSA. We describe the real-world use of dalba in patients with ABSSSI, bloodstream infections (BSI), bone and joint infection (BJI), or other infections (OI) from a retrospective registry study of dalba.Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE) was a phase 4 observational, multicenter, retrospective cohort study of the real-world use of dalba in adults geographically spread across the US. Patients were treated entirely at the physicians’ discretion. Data were collected from 25 Mar 2017–27 Nov 2018 and included patient demographics, diagnosis, microbiology, antibiotic use, clinical outcome, and safety until 60 days after last dalba dose. A post hoc analysis applied definitions for clinical success and failure similar to the dalba phase 3 clinical trials.The Safety Population comprised 1168 patients treated at 31 healthcare sites. Of 957 evaluable patients, 815 (85.2%) had ABSSSI, 48 (5.0%) had BSI, 87 (9.0%) had BJI, and 7 (0.7%) had OI. Clinical success was achieved in 91.7%, 89.6%, 86.2%, and 100% of patients with ABSSSI, BSI, BJI, and OI, respectively . Median cumulative dose of dalba for the index infection was 1500 mg for all categories, most commonly as 1 infusion . 36.9% of patients with BSI and 58.6% with BJI received ≥ 2 infusions. Most patients were treated as outpatients . Mean (SD) total cost of care associated with dalba use  was 5261.2 (1604.55), 7710.5 (7144.1), 8393.5 (5296.8), and 6305.8 (3338.1) USD for patients with ABSSSI, BSI, BJI, and OI, respectively. Adverse events evaluated as possibly related to dalba were reported in 33/1168 (2.8%) patients: 29 (2.9%) with ABSSSI, and 4 (3.6%) with BJI.Dalba demonstrated high rates of clinical success and safety in the real-world setting when used to treat patients for suspected or confirmed Gram-positive infections.Bruce M. Jones, Pharm.D., FIDSA, BCPS, AbbVie: Advisor/Consultant|AbbVie: Honoraria|La Jolla: Honoraria|Melinta: Advisor/Consultant|Paratek: Honoraria|Regeneron: Honoraria Kerry O. Cleveland, MD, AbbVie: Honoraria|Cumberland: Honoraria|Merck: Honoraria|Pfizer: Honoraria Pedro L. Gonzalez, MD, MT, AbbVie: Employee of AbbVie at the time of study conduct and analysis.|AbbVie: Stocks/Bonds|Becton Dickinson: Employee Urania Rappo, MD, AbbVie: Employee of Allergan, before its acquisition by AbbVie, at the time of study conduct and analysis|BiomX: Employee Todd Riccobene, PhD, AbbVie: Employee|AbbVie: Stocks/Bonds Rosie D. Lyles, MD, MHA, MSc, AbbVie: AbbVie Employee|AbbVie: Stocks/Bonds.


Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. J Immunother Cancer 2021;9:e002673. doi: 10.1136/jitc-2021-002673Roulstone V, Mansfield D, Harris RJ, Victoria Roulstone and David Mansfield are now listed as joint first authors.


J Immunother Cancer 2021;9:e003594. doi: 10.1136/jitc-2021-003594.Boughdad S, Latifyan S, Fenwick C, This article has been corrected since it was first published online. The acknowledgements have been removed, as consent was not provided.


Following publication of the original article , the autStatistical analysis subsection under the Methods section:Original: Adjusted HRs and RRs and corresponding 95% CIs between groups were also estimated including the treatment initiation group and covariates in the pre-index period .Corrected to: Adjusted HRs and RRs and corresponding 95% CIs between groups were also estimated including the treatment initiation group and covariates in the pre-index period .Table 1:Original: Number of patients in hospital owing to non-COPD exacerbations or acute respiratory failureCorrected to: Number of hospitalizations excluding hospitalization due to COPD exacerbation or acute respiratory failureFootnotes of Tables 2, 3, 4, and Additional file Original: Covariates in pre-index period include age, sex, number of comorbidities, use of systemic corticosteroids, use of antibiotics, and number of patients in hospital owing to non-COPD exacerbations or acute respiratory failureCorrected to: Covariates in pre-index period include age, sex, number of comorbidities, use of systemic corticosteroids, use of antibiotics, and number of hospitalizations excluding hospitalization due to COPD exacerbation or acute respiratory failureAdditional file Table 3 footnote:aCalculated by Cox proportional hazards modelOriginal: aCalculated by negative binomial modelCorrected to: Author contributions:The last sentence in the Author contributions section of the original article, “All authors read and approved the final manuscript.” has been deleted as this text is already a part of the previous sentence.Reference 7:A period has been added before the journal name.Original: Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group Lancet. 1998;351(9105):773–80.Corrected to: Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998;351(9105):773–80.Reference 9:“et al” has been added to the end of the author list.Original: Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017, et al. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–35.Corrected to: Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–35.Reference 12:“et al” has been added to the end of the author list.Original: Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, et al; ECLIPSE Study Investigators. Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. Eur Respir J. 2018;51(2):1702146.Corrected to: Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, ECLIPSE Study Investigators, et al. Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. Eur Respir J. 2018;51(2):1702146.Reference 22:“prompt” in the article title has been revised to title case as “Prompt”Original: Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, et al. PRIMUS—prompt Initiation of Maintenance Therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:329–42.Corrected to: Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, et al. PRIMUS—Prompt Initiation of Maintenance Therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:329–42.The original article has been corrected.Additional file 1: Table S1. ICD-10 codes. ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Table S2. ATC classification codes. ATC, Anatomical Therapeutic Chemical; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, longacting muscarinic antagonist; SABA, short-acting β2-agonist; SAMA, shortacting muscarinic antagonist. Table S3. Proportion of delayed therapy patients who used long-/short-acting bronchodilators before exacerbation. Table S4. Hazard ratios for exacerbations in subgroups stratified by periods of grouping. COPD, chronic obstructive pulmonary disease; CI, confidence interval. aCalculated by Cox proportional hazards model. Covariates in pre-index period include age, sex, number of comorbidities, use of systemic corticosteroids, use of antibiotics, and number of hospitalizations excluding hospitalization due to COPD exacerbation or acute respiratory failure.


Dermatosis in dialytic chronic kidney failure”1,with DOI code number https://doi.org/10.1590/2175-8239-JBN-2021-0227, published in theBrazilian Journal of Nephrology, ahead of print, 2022:In the article “Where it was written:shronicusLichen simplex Should read:chronicusLichen simplex


Translational Psychiatry 10.1038/s41398-021-01606-1, published online 15 September 2021Correction to: The original version of this article unfortunately contained an error in the references. Reference 12 should read as follows: Rutherford BR, Choi CJ, Choi J, Maas B, He X, O’Boyle K, et al. Slowed processing speed disrupts patient expectancy in late life depression. Am J Geriatr Psychiatry. 2021;29:619–30. The original article has been corrected.


The correct name is: Robinson de Jesús-Romero. The correct citation is: Howard J, de Jesús-Romero R, Peipert A, Riley T, Rutter LA, Lorenzo-Luaces L (2021) The significance of anxiety symptoms in predicting psychosocial functioning across borderline personality traits. PLoS ONE 16(1): e0245099. The publisher apologizes for the error.


Correction: BMC Psychiatry 15, 15 (2015).https://doi.org/10.1186/s12888-015-0394-0Following publication of the original article , the aut6. Oldenburg, B., OʼNeil, A., & Cocker, F. (2015). Public health perspectives on the co-occurrence of noncommunicable diseases and common mental disorders. In Comorbidity of mental and physical disorders . Karger Publishers.The original article  has been


Correction: BMC Complement Med Ther 22, 263 (2022)https://doi.org/10.1186/s12906-022-03746-3Following publication of the original article , the autIn the reference list, reference information below that was indicated in Table 4 has been added.Liu EH, Turner LM, Lin SX, Klaus L, Choi LY, Whitworth J, et al. Use of alternative medicine by patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2000;120:335–41.The original article  has been


Correction: Respiratory Research (2022) 23:300 https://doi.org/10.1186/s12931-022-02223-2Following publication of the original article , the autThe incorrect citation is: Viktoria Z, Stefanie D, Rosa BW, Cornelia LF, Wilfried P, Doris W.The correct citation is: Zaderer, V., Dichtl, S., Bellmann-Weiler, R., Lass-Flörl, C., Posch, W., Wilflingseder, D.The author group has been updated above and the original article  has been


Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem with activity against Enterobacterales uropathogens, including drug resistant strains. The ADAPT-PO trial demonstrated the non-inferiority of oral TBP-PI-HBr vs. intravenous (IV) ertapenem (ERT) in treating patients with cUTI and/or acute pyelonephritis (AP). Patients with certain anatomical disorders, functional  disorders and/or urinary tract instrumentation  are at increased risk for poor outcomes and recurrent bacteriuria. This secondary analysis of ADAPT-PO evaluated outcomes in patients with various cUTI risk factors.ADAPT-PO was a Phase 3 multinational, double-blind, double-dummy trial evaluating oral TBP-PI-HBr vs. IV ERT in 1372 hospitalized adult patients with cUTI/AP. Patients were randomized 1:1 to oral TBP-PI-HBr or IV ERT for 7-10 days. The primary efficacy endpoint was overall response  in the microbiological intent-to-treat (micro-ITT) population. Overall outcomes were assessed among patients with identified with at least one cUTI risk factor at baseline.At baseline, 382/449 (85.1%) and 361/449(86.2%) of patients in the TBP-PI-HBr and ERT arms, respectively had ≥1 risk factor and 289 (64.4%) and 268 (64.2%) had ≥2 risk factors. Anatomical abnormalities and/or urinary track instrumentation were present in 252 (56.1%) TBP-PI-HBr and 242 (57.8%) ERT patients; functional abnormalities were present in 90 (20.0%) and 85(20.3%) respectively). Among patients with ≥1 risk factor, overall response at TOC was 56.3% and 59.6% with TBP-PI-HBr and ERT, respectively, vs. 73.1% and 74.1% among those with no risk factors. Clinical response rates at TOC were high and similar in both arms in patients with (≥92.9%) and without (≥91.4%) risk factors whereas microbiologic responses were more variable between the 2 subsets.In cUTI patients with ≥1 risk factor for complicated disease at baseline, outcomes were comparable between oral TBP-PI-HBr and IV ERT. As expected, these patients were at higher risk for recurrent bacteriuria. Overall responses in both groups were higher among patients without these risk factors.Angela K. Talley, MD, Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds Paul B. Eckburg, MD, AN2 Therapeutics: Stocks/Bonds|Spero Therapeutics: Advisor/Consultant Ian A. Critchley, PhD, Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds Ian A. Critchley, PhD, Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds Gary E. Moore, PhD, Spero Therapeutics: Advisor/Consultant Nivedita Bhatt, PhD, Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds Lori A. Muir, B.Sc., Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds Lori A. Muir, B.Sc., Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds David Melnick, MD, Spero Therapeutics: Employee|Spero Therapeutics: Stocks/Bonds.


Correction to: BMC Health Serv Res 22, 478 (2022)https://doi.org/10.1186/s12913-022-07886-7Following publication of the original article , the autThe sentence originally read:less formally educated, and Medi-Cal-ineligible clients drove longer to treatment.Young, male, The sentence should read:more formally educated, and Medi-Cal-ineligible clients drove longer to treatment.Young, male, The original article  has been


Nature Communications 10.1038/s41467-022-34771-y, published online 08 December 2022Correction to: In this article the affiliation ‘Present address: Structural Biology Division, Japan Synchrotron Radiation Research Institute, SPring-8; Sayo, Hyogo, Japan” for Hideki Shigematsu was missing.The original article has been corrected.


Scientific Reports 10.1038/s41598-022-19201-9, published online 20 September 2022Correction to: The original version of this Article contained an error in Reference 22, which was incorrectly given as:J. Med. Chem.63, 15333–15343 (2020).Luca, S. D., Verdoliva, V. & Saviano, M. Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives. The correct reference is listed below:J. Med. Chem.63, 15333–15343 (2020).De Luca, S., Verdoliva, V. & Saviano, M. Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives. The original Article has been corrected.


The correct name is: Francis L Martin. The correct citation is: Holden CA, Bailey JP, Taylor JE, Martin FL, Beckett P, McAinsh M (2022) Know your enemy: Application of ATR-FTIR spectroscopy to invasive species control. PLoS ONE 17(1): e0261742.


S. maltophilia has become a major cause of hospital-associated pneumonia. Aztreonam (ATM) is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs), including those intrinsically produced by S. maltophilia. Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that inhibits serine β-lactamases such as ESBLs, KPCs, AmpCs, and some OXAs. ATM-AVI is being developed for treatment of serious infections caused by Gram-negative bacteria, including MBL producers. We evaluated the activity of ATM-AVI against S. maltophilia and B. cepacia from US hospitals.S. maltophilia and 219 B. cepacia were consecutively collected (1/patient) in 77 US medical centers in 2016-2021 and susceptibility tested by CLSI broth microdilution method. Only isolates determined to be the probable cause of infection were included. CLSI/US FDA breakpoints were applied when available.1,565 S. maltophilia, with MIC50/90s of 2/4 mg/L and 98.3% of isolates inhibited at ≤8 mg/L, including 100.0% of isolates from BSI and 97.9% of isolates from pneumonia. Trimethoprim-sulfamethoxazole  and minocycline  also were very active against S. maltophilia, while ceftazidime and levofloxacin were active against 21.3% and 76.2% of isolates per CLSI criteria, respectively (Table). ATM-AVI was also very active against B. cepacia, with MIC50/90s of 4/16 mg/L and 88.1% inhibited at ≤8 mg/L, including 93.3% and 87.3% of isolates from BSI and pneumonia, respectively. The most active comparators tested against B. cepacia were ceftazidime (84.9%S), meropenem (84.5%S), TMP-SMX (83.5%S), and minocycline (80.0%S).The isolate collection were recovered mainly from patients with pneumonia (73.3%) and bloodstream infection . ATM-AVI was very active against in vitro activity against S. maltophilia and B. cepacia from US hospitals and may represent a valuable option to treat infections caused by these organisms. Clinical studies are urgently warranted to evaluate the efficacy of ATM-AVI as well as reevaluate the susceptibility breakpoints for antibiotics currently used to treat infections caused by these organisms.ATM-AVI demonstrated potent Helio S. Sader, MD, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Pfizer: Grant/Research Support Dee Shortridge, PhD, AbbVie: Grant/Research Support|JMI Laboratory: Employee|Melinta: Grant/Research Support|Menarini: Grant/Research Support|Shionogi: Grant/Research Support SJ Ryan Arends, PhD, AbbVie: Grant/Research Support|GSK: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Shionogi: Grant/Research Support Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Office for Assistant Secretary of Defense for Health Affairs: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support|Spero Therapeutics: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support.


Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD Open 2022;8:e002593. doi: 10.1136/rmdopen-2022-002593Simons G, Janssen EM, Veldwijk J, The funding statement for this article has been updated.


Four other β-lactamase inhibitor combinations (BL/BLI) have been recently approved by the US FDA: ceftazidime-avibactam (CAZ-AVI), ceftolozane-tazobactam (C-T), meropenem-vaborbactam (MEM-VAB), and imipenem-relebactam (IMI-REL). We evaluated the n=187) and 12 European countries  in 2018-2021 and susceptibility tested by CLSI broth microdilution method.383 PSA isolates (1/patient) were recovered from 35 medical centers in the US  was the most active agent, followed by IMI-REL (94.7%/92.5%S in US/EU) and C-T (89.8%/91.3%S in US/EU). MEM-VAB (not approved for PSA in the US) and MEM showed similar activity. Tobramycin (TOB)-S rates were 73.3%/85.7% in US/EU (Table 1). Among TOB-non-S (NS) isolates, 84.6% were CAZ-AVI-S and 73.1% were inhibited at ATM-AVI MIC of ≤8 mg/L. CAZ-AVI retained good activity against C-T-NS (61.1%S), IMI-REL-NS (62.1%S), piperacillin-tazobactam (PIP-TAZ)-NS (86.7%S), meropenem (MEM)-NS (86.6%S), and ciprofloxacin (CIP)-NS (92.1%S) isolates (Table 2). Multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes were observed among 40.1%/30.1% and 24.6%/16.8% of isolates from US/EU, respectively. Among MDR isolates, 90.7%/84.7% were CAZ-AVI-S, 65.3%/66.1% were inhibited at ≤8 mg/L of ATM-AVI, and 78.7%/76.3% were TOB-S in US/EU. CAZ-AVI and TOB retained activity against 87.0%/75.8% and 39.1%/63.6% of XDR isolates in US/EU, respectively.ATM-AVI inhibited 83.4%/85.2% of isolates from US/EU at ≤8 mg/L. CAZ-AVI (MICATM-AVI and CAZ-AVI exhibited potent activity against PSA isolated from CF patients in US and EU and retained good activity against isolates resistant to other antimicrobials, including MDR and XDR organisms; both compounds showed greater activity than TOB. ATM-AVI and CAZ-AVI may represent a valuable option to treat CF patients with pulmonary exacerbations due to PSA infection.Helio S. Sader, MD, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Pfizer: Grant/Research Support Leonard R. Duncan, PhD, AbbVie: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Office for Assistant Secretary of Defense for Health Affairs: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support|Spero Therapeutics: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support.


While a 3-dose mRNA-1273 primary series is recommended for moderately or severely immunocompromised (IC) individuals in the U.S., some IC individuals do not complete the 3-dose series. We conducted a matched cohort study to evaluate the relative vaccine effectiveness (rVE) of the 3-dose mRNA-1273 primary series vs. 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection and severe COVID-19 disease in IC individuals.nd dose date. Third doses were accrued from 08/12/2021 to 12/31/2021, with follow-up through 1/31/2022, spanning the delta and omicron periods. Outcomes were SARS-CoV-2 infection (positive molecular test or diagnosis code), COVID-19 hospitalization, and COVID-19 hospital death. Adjusted hazard ratios (aHR) with confidence intervals (CI) were estimated by Cox proportional hazards models. Adjusted rVE (%) was calculated as (1-aHR) x 100.IC individuals aged ≥18 years with ≥12 months of Kaiser Permanente Southern California membership who received 3 doses of mRNA-1273 ≥24 days apart were 1:1 matched with randomly selected IC 2-dose recipients on age, sex, race/ethnicity, and 2rd dose (Table 3).Our study included 21,942 3-dose and 21,942 2-dose mRNA-1273 IC recipients. Adjusted rVE of 3 doses compared to 2 doses of mRNA-1273 against SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospital death were 55.0% (95% CI: 50.8–58.9%), 83.0% (75.4–88.3%), and 87.1% (30.6–97.6%), respectively (Table 1). Adjusted rVE against SARS-CoV-2 infection ranged from 43.0% to 59.1% across subgroups of age, sex, race/ethnicity, history of SARS-CoV-2 infection, pregnancy, and comorbidities (Table 2). Point estimates of the 3-dose rVE were higher against COVID-19 infection and hospitalization in the first 3 months, compared to 3–6 months after the 3rd primary series dose for adequate protection of IC individuals.Three doses of mRNA-1273 provide additional protection against SARS-CoV-2 infection and severe outcomes for IC individuals, compared to 2 doses, highlighting the importance of completing 3-doses for IC populations. However, possible waning of protection against SARS-CoV-2 infection and severe outcomes after 3 months supports the ACIP recommendation of a booster dose at least 3 months after the 3Jennifer H. Ku, PhD MPH, GSK: Grant/Research Support|Moderna: Grant/Research Support Lina S. Sy, MPH, Dynavax: Grant/Research Support|Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support|Seqirus: Grant/Research Support Lei Qian, PhD, Dynavax: Grant/Research Support|Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support Bradley Ackerson, MD, Dynavax: Grant/Research Support|Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support|Seqirus: Grant/Research Support Yi Luo, PhD, Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support|Seqirus: Grant/Research Support Julia Tubert, MPH, Moderna: Grant/Research Support|Pfizer: Grant/Research Support Gina Lee, MPH, Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support Ana Florea, PhD MPH, Gilead: Grant/Research Support|GSK: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support Carla Talarico, PhD, Moderna: Employee of and a shareholder in Moderna Inc. Sijia Qiu, MS, Dynavax: Grant/Research Support|Moderna: Grant/Research Support Yun Tian, MS, Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support Hung Fu Tseng, PhD MPH, GSK: Grant/Research Support|Janssen: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Advisor/Consultant|Seqirus: Grant/Research Support.


Neotoxosceluspetilussp. nov. is described from South Korea. Neotoxoscelus Fisher, 1921 is also a new generic record for South Korea. A key to the Neotoxoscelus species and an updated checklist are provided. Neotoxoscelus Fisher, 1921  is a small group, with only seven known species globally. Most of these species are distributed in Oriental Region: N.aeneiventris Fisher, 1930, N.bakeri Fisher, 1921, N.corporaali Obenberger, 1922, N.kurosawai , N.luzonicus Fisher, 1921, and N.ornatus Fisher, 1930, with only N.kerzhneri  reported from the Palaearctic Region , had been reported from South Korea , Daegu, Gyeongsangbuk-do, South Korea.The specimen was collected in Mt. Juwangsan, Cheongsong-gun, Gyeongsangbuk-do province, South Korea Fig.  by sweepBody length: distance from apex of head to apex of elytra.Elytral length: distance from anterior margin to apex of elytra.Elytral width: width of both elytra at widest point.Pronotal length: length of pronotum along midline.Pronotal width: width of pronotum at widest point.Buprestidae Leach, 1815Family Agrilinae Laporte, 1835Subfamily Coraebini Bedel, 1921Tribe Taxon classificationAnimaliaColeopteraBuprestidaeGenusFisher, 192162FECCD4-417C-5F27-B4DE-E950021C3000NeotoxoscelusNeotoxoscelusbakeri Fisher, 1921 . Fisher, 1921: 418. Type species: Pronotum convex; inner margin of all tibiae almost straight; no space between tibiae and femora when closed; apical margin of pygidium with a short spinous process in middle part .Taxon classificationAnimaliaColeopteraBuprestidae9160B56F-68B0-538C-8DBC-599E26B69682https://zoobank.org/8141964D-10A7-4672-8C08-C542815299BBN.kerzhneri  among its congeners. It can be distinguished from N.kerzhneri based on the following combination of morphological characters: body slender; lateral margin of pronotum slightly curved and narrowed with somewhat distinct sinuation, basal angle rounded; scutellum wider than long; elytra widest at humerus, longer than wide: W/L = 2.60 (width at humerus), W/L = 2.40 (width including laterosternites); median lobe of male genitalia with two pointed apical denticles on each side and lateral margin slightly narrowed. In contrast, N.kerzhneri has the following aspects: stout body; lateral margin of pronotum more roundly curved and rectilinearly narrowed, without sinuation, basal angle angulated; scutellum longer than wide; elytra widest at posterior 5/9, longer than wide: W/L = 2.35–2.40 (width at humerus), W/L = 2.04–2.16 (width including laterosternites); median lobe of male genitalia without apical denticles on each side and lateral margin drastically narrowed .Unknown.South Korea, Gyeongsangbuk-do province.The specific epithet refers to the slender body shape of the new species.Neotoxoscelusaeneiventris Fisher, 1930Distribution. Malaysia (Pahang).Neotoxoscelusbakeri Fisher, 1921Distribution. Philippines (Mindanao).Neotoxosceluscorporaali Obenberger, 1922Distribution. Indonesia (Sumatura).Neotoxosceluskerzhneri Distribution. China , Mongolia (Dornogovi).Neotoxosceluskurosawai Distribution. Taiwan.Neotoxoscelusluzonicus Fisher, 1921Distribution. Philippines (Luzon).Neotoxoscelusornatus Fisher, 1930Distribution. Malaysia (Sabah).Neotoxosceluspetilus sp. nov.Distribution. South Korea.